153 related articles for article (PubMed ID: 35810832)
1. De novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2022 Sep; 127():112-122. PubMed ID: 35810832
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: de novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors of the prostate.
Fine SW
Mod Pathol; 2018 Jan; 31(S1):S122-132. PubMed ID: 29297494
[TBL] [Abstract][Full Text] [Related]
4. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.
Priemer DS; Montironi R; Wang L; Williamson SR; Lopez-Beltran A; Cheng L
Endocr Pathol; 2016 Jun; 27(2):123-35. PubMed ID: 26885643
[TBL] [Abstract][Full Text] [Related]
6. Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma.
Bellur S; Van der Kwast T; Mete O
Hum Pathol; 2019 Mar; 85():313-327. PubMed ID: 30481509
[TBL] [Abstract][Full Text] [Related]
7. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].
Campedel L; Kossaï M; Blanc-Durand P; Rouprêt M; Seisen T; Compérat E; Spano JP; Malouf G
Bull Cancer; 2017 Sep; 104(9):789-799. PubMed ID: 28673439
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging therapies for neuroendocrine prostate cancer.
Alabi BR; Liu S; Stoyanova T
Pharmacol Ther; 2022 Oct; 238():108255. PubMed ID: 35905791
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
11. Primary Prostatic Carcinoma With De Novo Diffuse Neuroendocrine Differentiation.
Galea LA; Mow C; Fine SW; Manohar P
Int J Surg Pathol; 2022 Apr; 30(2):232-236. PubMed ID: 34338584
[TBL] [Abstract][Full Text] [Related]
12. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
[No Abstract] [Full Text] [Related]
13. Endocrine and paracrine characteristics of neuroendocrine prostate cancer.
Arman T; Nelson PS
Front Endocrinol (Lausanne); 2022; 13():1012005. PubMed ID: 36440195
[TBL] [Abstract][Full Text] [Related]
14. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
Tabrizi S; Alshalalfa M; Mahal BA; Davicioni E; Liu Y; Mouw KW; Feng F; Nguyen PL; Muralidhar V
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):936-940. PubMed ID: 32585335
[TBL] [Abstract][Full Text] [Related]
15. Large Cell Neuroendocrine Carcinoma of the Prostate: A Systematic Review and Pooled Analysis.
Tu X; Chang T; Nie L; Qiu S; Xu H; Huang Y; Bao Y; Liu Z; Yang L; Wei Q
Urol Int; 2019; 103(4):383-390. PubMed ID: 30965328
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
17. Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.
Monn MF; Cheng L
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1029-37. PubMed ID: 27534689
[TBL] [Abstract][Full Text] [Related]
18.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
19. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
